Evolution of Patiromer Use: a Review

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hyperkalemia is a common complication of RAAS inhibitor therapy, often necessitating treatment discontinuation.
• Resistant hypertension and heart failure management are frequently limited by hyperkalemia.
• Patiromer offers a novel approach to potassium binding, improving therapeutic options.

Purpose of the Study:

• To review clinical trial data supporting patiromer's use as a potassium binder.
• To highlight patiromer's role in enabling RAAS inhibitor therapy in patients with hyperkalemia.
• To discuss the impact of recent trials, such as AMBER and DIAMOND, on patiromer's clinical application.

Main Methods:

• Review of clinical trial data, including the AMBER and DIAMOND studies.
• Analysis of patiromer's efficacy and tolerability in diverse patient populations.
• Stratification of participants based on serum potassium levels, diabetes, and chronic kidney disease.

Main Results:

• Patiromer is a well-tolerated potassium binder, superior to older agents.
• The AMBER trial demonstrated benefits of patiromer in resistant hypertension patients.
• Patiromer enables the use of life-saving RAAS inhibitors in patients with hyperkalemia.

Conclusions:

• Patiromer is a valuable tool for managing hyperkalemia, facilitating essential cardiovascular and kidney disease treatments.
• Clinical data support patiromer's chronic use in patients requiring RAAS inhibitors.
• Patiromer improves patient outcomes by allowing continued access to critical therapies.